Journal
MOLECULAR CANCER RESEARCH
Volume 13, Issue 9, Pages 1274-1282Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-15-0061
Keywords
-
Categories
Funding
- NIH Cancer Center Support Grant [CA016672]
- NIH [R01CA157880, T32CA009599]
- Department of Defense [CA100879]
- William C. Liedtke, Jr., Chair in Cancer Research
- Texas Medical Center-Digestive Disease Center pilot award
Ask authors/readers for more resources
A large number of pseudogenes have been found to be transcribed in human cancers. However, only a few pseudogenes are functionally characterized. Here, we identified a transcribed pseudogene of VEGFR1, or fms-related tyrosine kinase 1 (FLT1), in human colorectal cancer cells. Interestingly, this pseudogene (designated as FLT1P1) was found to be transcribed bidirectionally and functionally modulated cognate VEGFR1 protein expression in the cells. Mechanistically, expression of FLT1P1 antisense transcript not only inhibited the VEGFR1 expression, but also inhibited non-cognate VEGF-A expression through interaction with miR-520a. Perturbation of FLT1P1 expression by RNA inter-xenograft tumor growth. This study identifies FLT1P1 antisense as a critical regulator of VEGFR1 and VEGF-A expression in colorectal cancer cells, and highlights its role in regulation of the pathogenesis of colorectal cancer. Implications: The VEGFR1 pseudogene, FLT1P1, is a novel and functional regulator of VEGF signaling and its targeting could be an alternative strategy to modulate its cognate/target gene expression and downstream activity in cancer. (C) 2015 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available